Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma

Journal of Nuclear Medicine

Volumn 53, Issue 2, 2012, Pages 215-224

  Senthamizhchelvan, Srinivasan ^a   Hobbs, Robert F ^a   Song, Hong ^a   Frey, Eric C ^a   Zhang, Zhe ^b   Armour, Elwood ^a   Wahl, Richard L ^a,c   Loeb, David M ^b   Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

153Sm; Osteosarcoma; Radiobiologic dosimetry; Radiopharmaceutical therapy

Indexed keywords

LEXIDRONAM SAMARIUM SM 153;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HIGH RISK PATIENT; HUMAN; IMAGE RECONSTRUCTION; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RECURRENT CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE; TUMOR DOSIMETRY; TUMOR VOLUME;

ADULT; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; MALE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RISK; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863079318     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.096677     Document Type: Article

References (28)

1. PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis. 2011;28:493-503.
2. Loeb DM, Hobbs RF, Okoli A, et al. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer. 2010;116:5470-5478.
3. 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009;115:2514-2522.
4. Coronado M, Redondo A, Coya J, et al. Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease. Clin Nucl Med. 2006;31:605-610. (Pubitemid 44427353)
5. Sartor O. Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol. 2004;6:S3-S12.
6. Welsh JS, Thurman SA, Borzillary S, Schwartz CL, Howard SP. Sm-153 EDTMP for recurrent metastatic osteosarcoma. Clin Adv Hematol Oncol. 2003;1:181-183.
7. Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer. 2000;88:2934-2939. (Pubitemid 30413176)
8. Franzius C, Bielack S, Sciuk J, Vollet B, Jurgens H, Schober O. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma. Nuklearmedizin. 1999;38:337-340.
9. Ogawa Y, Takahashi T, Kobayashi T, et al. Mechanism of apoptotic resistance of human osteosarcoma cell line, HS-Os-1, against irradiation. Int J Mol Med. 2003;12:453-458.
10. Singh A, Holmes RA, Farhangi M, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med. 1989;30:1814-1818.
11. O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med. 1999;40:1337-1341. (Pubitemid 29385643)
12. Prideaux AR, Song H, Hobbs RF, et al. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007;48:1008-1016. (Pubitemid 46909931)
13. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med. 2010;51:1155-1162.
14. Hobbs RF, Baechler S, Senthamizhchelvan S, et al. A gamma camera count rate saturation correction method for whole-body planar imaging. Phys Med Biol. 2010;55:817-831.
15. He B, Du Y, Song X, Segars WP, Frey EC. A Monte Carlo and physical phantom evaluation of quantitative In-111 SPECT. Phys Med Biol. 2005;50:4169-4185. (Pubitemid 41225264)
16. Eckerman KF, Endo A. MIRD: Radionuclide Data and Decay Schemes. 1st ed. Reston, VA: Society of Nuclear Medicine; 2008.
17. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679-694. (Pubitemid 19194494)
18. Hobbs RF, Sgouros G. Calculation of the biological effective dose for piecewise defined dose-rate fits. Med Phys. 2009;36:904-907.
19. Brenner DJ, Hall EJ. Conditions for the equivalence of continuous to pulsed low dose rate brachytherapy. Int J Radiat Oncol Biol Phys. 1991;20:181-190.
20. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53:983-997. (Pubitemid 27391027)
21. Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol. 1989;7:1926-1931. (Pubitemid 20014342)
22. Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993;34:1031-1036. (Pubitemid 23191314)
23. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med. 1994;35:63-69. (Pubitemid 24018442)
24. Sgouros G, Frey E, Wahl R, He B, Prideaux A, Hobbs R. Three-dimensional imaging-based radiobiological dosimetry. Semin Nucl Med. 2008;38:321-334. (Pubitemid 352033565)
25. Bartlett M, Webb M, Durrant S, Morton J, Allison R, Macfarlane D. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies. Eur J Nucl Med Mol Imaging. 2002;29:1470-1477. (Pubitemid 35232049)
26. Erwin W, Mikell J, Ueno N. Predictive value of a pre-therapy tracer study skeletal retention estimate in high-dose Sm-153 EDTMP radiotherapy of skeletal metastatic breast cancer [abstract]. J Nucl Med. 2010;51:204P.
27. Ciernik IF, Niemierko A, Harmon DC, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer. 2011;117:4522-4530.
28. Hobbs RF, McNutt T, Baechler S, et al. A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy. Int J Radiat Oncol Biol Phys. 2011;80:1256-1262.